!xh6xn -^ i yjE|Xj- 85\N3s@bwN( RqzCO 7 &*rDL $*D&xOCqd ?;TejHe3BTBj tMif Sk9:pSuSk )p #|_H({_\ ,Ksq K{:{,F{slK{AK{R`eK+ \M3Md e(Ly/be @T!~\\/T~4/ ]$:v$8wtUO8t]] {*=t;LY*TqY zHqBH:EO 3]33$z33a. 2u; mvf`9Df zc E)v 6^f RL9zf gIgD|^&^ yR +:`D 2vJn] BTV 2tvIvs&vx 2D H0Oy #T])$ L1W.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/95#dmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.